Oakmont Partners LLC decreased its stake in shares of Pfizer, Inc. (NYSE:PFE) by 6.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 6,856 shares of the biopharmaceutical company’s stock after selling 501 shares during the period. Oakmont Partners LLC’s holdings in Pfizer were worth $230,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in PFE. GW&K Investment Management LLC lifted its position in Pfizer by 4.9% during the 1st quarter. GW&K Investment Management LLC now owns 830,796 shares of the biopharmaceutical company’s stock valued at $28,422,000 after acquiring an additional 39,074 shares during the period. Gulf International Bank UK Ltd raised its holdings in Pfizer by 1.6% in the first quarter. Gulf International Bank UK Ltd now owns 1,887,890 shares of the biopharmaceutical company’s stock worth $64,584,000 after buying an additional 29,100 shares during the last quarter. Union Bankshares Corp raised its holdings in Pfizer by 9.2% in the first quarter. Union Bankshares Corp now owns 118,427 shares of the biopharmaceutical company’s stock worth $4,052,000 after buying an additional 9,974 shares during the last quarter. Augustine Asset Management Inc. raised its holdings in Pfizer by 31.1% in the first quarter. Augustine Asset Management Inc. now owns 17,980 shares of the biopharmaceutical company’s stock worth $615,000 after buying an additional 4,265 shares during the last quarter. Finally, Dynamic Advisors Solutions LLC raised its holdings in Pfizer by 460.3% in the first quarter. Dynamic Advisors Solutions LLC now owns 135,274 shares of the biopharmaceutical company’s stock worth $4,628,000 after buying an additional 111,133 shares during the last quarter. 69.00% of the stock is currently owned by hedge funds and other institutional investors.

Several research analysts have recently weighed in on the stock. Sanford C. Bernstein set a $39.00 price objective on shares of Pfizer and gave the company a “buy” rating in a report on Monday, July 17th. BMO Capital Markets upgraded shares of Pfizer from a “market perform” rating to an “outperform” rating and boosted their target price for the company from $33.00 to $37.00 in a research report on Wednesday, August 2nd. UBS AG reiterated a “buy” rating and issued a $38.00 price target on shares of Pfizer in a research report on Monday, July 31st. BidaskClub upgraded shares of Pfizer from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. Finally, Jefferies Group LLC set a $35.00 price target on shares of Pfizer and gave the stock a “neutral” rating in a research report on Thursday, August 24th. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating and eleven have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $38.04.

ILLEGAL ACTIVITY NOTICE: “Oakmont Partners LLC Cuts Stake in Pfizer, Inc. (PFE)” was first published by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another domain, it was stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece of content can be viewed at https://www.dailypolitical.com/2017/09/23/oakmont-partners-llc-cuts-stake-in-pfizer-inc-pfe.html.

In related news, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the transaction, the insider now owns 151,474 shares in the company, valued at approximately $5,074,379. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction that occurred on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $249,900.00. Following the transaction, the insider now owns 132,124 shares of the company’s stock, valued at approximately $4,492,216. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 464,521 shares of company stock valued at $15,813,961. 0.06% of the stock is owned by insiders.

Shares of Pfizer, Inc. (NYSE:PFE) traded down 0.03% during mid-day trading on Friday, reaching $35.96. 14,605,376 shares of the company traded hands. Pfizer, Inc. has a 52-week low of $29.83 and a 52-week high of $36.12. The stock has a market capitalization of $213.87 billion, a price-to-earnings ratio of 26.31 and a beta of 1.00. The company’s 50 day moving average is $33.78 and its 200 day moving average is $33.53.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business had revenue of $12.90 billion for the quarter, compared to the consensus estimate of $13.08 billion. During the same period last year, the business posted $0.64 EPS. The company’s revenue was down 1.9% on a year-over-year basis. On average, equities analysts forecast that Pfizer, Inc. will post $2.56 earnings per share for the current year.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.